Fungal infections claim an estimated 1.5 million lives each year. Mechanisms that protect from fungal infections are still elusive. Recognition of fungal pathogens relies on C-type lectin receptors (CLRs) and their downstream signaling kinase SYK. Here we report that the E3 ubiquitin ligase CBLB controls proximal CLR signaling in macrophages and dendritic cells. We show that CBLB associates with SYK and ubiquitinates SYK, dectin-1, and dectin-2 after fungal recognition. Functionally, CBLB deficiency results in increased inflammasome activation, enhanced reactive oxygen species production, and increased fungal killing. Genetic deletion of Cblb protects mice from morbidity caused by cutaneous infection and markedly improves survival after a lethal systemic infection with Candida albicans. On the basis of these findings, we engineered a cell-permeable CBLB inhibitory peptide that protects mice from lethal C. albicans infections. We thus describe a key role for Cblb in the regulation of innate antifungal immunity and establish a novel paradigm for the treatment of fungal sepsis. 
Fungal infections constitute a severe health threat, especially to people with an impaired immune status, as observed after HIV infection 1 , immune suppression 2 , or primary immune deficiencies 3 . Candida species are the second most prevalent agents of fungal infections worldwide, and C. albicans is the most frequently isolated pathogen from patients suffering from severe forms of fungal infections in the developed world 4 . Gaining mechanistic insights into the immune response mounted toward this class of pathogens is thus of considerable interest in uncovering novel treatment options.
The initiation of an immune response toward fungal pathogens relies on the recognition of fungal pathogen-associated molecular patterns. By using gene-deficient mice, toll-like receptors (TLRs) and CLRs have been proven to be essential for fungal recognition [5] [6] [7] [8] [9] . The CLRs dectin-1 (ref. 10) , dectin-2 (ref. 11) , and dectin-3 (ref. 12 ), Mincle 13 , and mannose receptor, C type 1 (MRC1) 14 recognize various constituents of the fungal cell wall, including β-glucan 10 , hyphal mannose 12 , and glycolipids 15 to initiate protective immunity. Although dectin-1, dectin-2, dectin-3, and Mincle are essential for immune reactions against disseminated candidiasis, mannose-receptor-deficient (Mrc1 −/− ) mice mount a comparatively normal immune response. The mannose receptor seems to be essential for T H 17-type immunity, however 14, 16 , and defective T H 17 responses have been linked to an impairment in mucosal antifungal defense in both mice and humans 17, 18 .
Signaling induced by the CLRs dectin-1, dectin-2, dectin-3, and Mincle critically depends on activation of SYK 19 . SYK is recruited to receptor complexes and is activated by phosphorylation via sarcoma (SRC) family kinases and autophosphorylation 20 . Activated SYK then triggers the inflammasome 21, 22 , NF-κB transcription-factor-dependent signaling 23 and reactive oxygen species (ROS) production in phagocytes and neutrophils 19 . Collectively, the activation of SYK by CLRs causes an immediate activation of fungicidal pathways and induces cell-type-specific transcriptional changes to eradicate fungal infections.
The E3 ubiquitin ligase CBLB was initially characterized as a negative regulator of the adaptive immune response 24, 25 , as it could dampen both T cell and B cell receptor signaling 26 . Genetic ablation of Cblb 24, 25 , or knock-in of the allele encoding the catalytically inactive CBLB Cys373Ala variant 27 (Cblb C373A/C373A ), has thus been reported to cause autoimmunity. Recent observations uncovered additional roles for CBLB in NK cells 28 , mast cells 29 , integrin signaling 30 , and dendritic cells (DCs) 31 , extending the range of CBLB functions to cells of the innate immune system. Signaling molecules that are targeted by CBLB are often not specific to defined pathways but can be used by multiple signaling modules. For example, CBLB-mediated negative regulation of SYK activity has been described for several cell types 32, 33 . Although the regulation of SYK by CBLB has been well established in the context of adaptive immune responses, negative regulators of SYK in signal transduction events induced by pattern recognition receptors of the CLR superfamily have not been described yet.
Here we report that Cblb deficiency ameliorates fungal pathology during systemic and cutaneous C. albicans infections. CBLB functions in phagocytes by regulating the availability of dectin-1 and dectin-2, and their signaling via SYK. Notably, peptide-based inhibition of CBLB increased cellular responses to fungal stimulation in vitro and completely protected mice from morbidity and mortality after systemic infection with C. albicans.
RESULTS

Loss of CBLB protein or catalytic activity ameliorates fungal pathology
To test for a potential role of CBLB in antifungal immunity, we challenged Cblb −/− , Cblb C373A/C373A (which express catalytically inactive CBLB 27 ), and Cblb +/+ littermates ( Supplementary Fig. 1a ) systemically with a lethal dose of C. albicans. Loss of Cblb or expression of CBLB C373A markedly ameliorated fungal pathology, as compared to that in Cblb +/+ controls (Fig. 1a,b) . We also observed significantly reduced fungal burdens in affected organs of Cblb −/− mice, as compared to that in organs from their Cblb +/+ littermates (Fig. 1c) . Histopathologic analysis of kidneys 7 d after systemic infection confirmed these results; Cblb −/− mice manifested reduced renal inflammation (Fig. 1d,e ) and reduced numbers of C. albicans yeast cells and hyphae (Fig. 1f,g ). Additionally, we detected a significant reduction in neutrophil infiltration into the kidneys of infected Cblb −/− mice than in the kidneys of Cblb +/+ littermates (Fig. 1h,i and Supplementary  Fig. 1b ). Systemic infection with a lethal dose of a clinical isolate of Candida dubliniensis yielded similar results with respect to mortality kinetics for Cblb −/− mice, as compared to Cblb +/+ controls (Supplementary Fig. 1c ). To assess whether Cblb deficiency caused a broad de-regulation of innate immune function and not just in fungal infections, we infected Cblb-deficient and Cblb +/+ littermates with the bacterial pathogen Listeria monocytogenes. Loss of Cblb did not affect the mortality kinetics of the infected mice ( Supplementary  Fig. 1d ). Although these results do not exclude a role for Cblb in antibacterial immune responses in general, our results show that loss of Cblb results in marked resistance to systemic C. albicans and C. dubliniensis infections.
To gain insight into the cellular basis of the observed protective effect, we generated bone marrow (BM)-chimeric mice by reconstituting lethally irradiated Cblb +/+ mice with syngeneic Cblb −/− , Cblb C373A/C373A , or Cblb +/+ BM. Loss of Cblb in radiosensitive hematopoietic cells phenocopied full-body Cblb deficiency after systemic C. albicans infection (Fig. 2a,b) . To test for a contribution of CBLB in adaptive immune cells to the observed phenotype, we generated Cblb +/+ Rag2 −/− and Cblb −/− Rag2 −/− mice, which lack T cells and B cells. Notably, Cblb deficiency in the absence of adaptive immune cells closely resembled the full-body knockout phenotype after lethal C. albicans infection (Fig. 2c,d) , suggesting a role for Cblb in regulating the antifungal activity of innate immune cells. Additionally, for Cblb +/+ mice, and n = 5 for Cblb −/− mice. In h,i, n = 4 for Cblb +/+ mice, and n = 4 for Cblb −/− mice. In d-i, four sections per kidney were analyzed. In a,c,e,g,i, data are shown as mean ± s.d. In c-i, one representative experiment of three independent experiments is shown. *P < 0.05, **P < 0.01, ***P < 0.001; by two-way analysis of variance (ANOVA) (a), log-rank test (b), or Student's t-test (c,e,g,i).
In d,f,h, insets show higher-magnification images of boxed areas; scale bars, 2,000 µm, 50 µm (insets). BM-chimeric mice were generated by reconstituting irradiated Rag2 −/− recipients with Cblb −/− Rag2 −/− or Cblb +/+ Rag2 −/− BM to restrict Cblb deficiency to innate immune cells. We observed that loss of Cblb confers an innate-immune-system-intrinsic protective effect to systemic infection with C. albicans (Fig. 2e,f) .
To test for developmental effects of Cblb deficiency in immune cells that are relevant for antifungal defense, we assessed the cellular composition of the BM and spleen of Cblb −/− and Cblb +/+ mice. We observed slightly elevated levels of both BM and splenic neutrophils and of splenic NK cells in unchallenged 6-week-old mice ( Supplementary Fig. 1e,f) . To address whether increased steady-state numbers of these cells might affect organ infiltration by monocytes or neutrophils, we quantified their recruitment in response to systemic C. albicans challenge 24 h after infection. We observed comparable immune infiltration in the kidneys, lungs, and livers of Cblb −/− and Cblb +/+ mice ( Supplementary Fig. 2a-c) . Recognition of cell wall β-glucan by dectin-1 has been shown to be essential for antifungal immune responses 10 . We detected comparable expression of dectin-1 on blood monocytes and neutrophils of Cblb −/− mice and their control Cblb +/+ littermates ( Supplementary  Fig. 2d,e) . Moreover, mRNA expression of Clec7a (encoding dectin-1), Clec4n (encoding dectin-2), Clec4d (encoding dectin-3), and Clec4e (encoding Mincle) were comparable in splenocytes and BM cells of Cblb −/− and Cblb +/+ mice ( Supplementary Fig. 2f,g) . Notably, although Cblb −/− and Cblb +/+ mice showed comparable early cellular recruitment, fungal burdens in affected organs were already markedly decreased 24 h after C. albicans infection (Supplementary Fig. 2h ), supporting the notion that loss of Cblb results in increased fungicidal activity of innate immune cells.
To test whether the protective effect of Cblb deficiency could be extended to other routes of infection, we used a model of cutaneous C. albicans infection 34 . We observed an increased resistance of Cblb −/− mice to skin colonization by C. albicans, as compared to that in Cblb +/+ controls, as evidenced by a significantly decreased fungal burden (Fig. 2g) . Because of the established role of adaptive immune cells in cutaneous antifungal immunity 34 , we performed C. albicans skin infections on a Rag2-deficient background. Notably, we observed a decreased fungal load in the skin of Cblb −/− Rag2 −/− mice, as compared to that in Cblb +/+ Rag2 −/− littermates (Fig. 2h) . Thus, loss of Cblb in innate immune cells confers resistance to systemic, as well as cutaneous, C. albicans infections.
Cblb controls the antifungal activities of dendritic cells and macrophages To directly investigate the effect of Cblb deficiency on the main fungicidal immune cell lineages 35 , we performed in vitro killing assays by co-culturing BM-derived macrophages (BM-Ms), BM-derived DCs (BM-DCs), neutrophils or monocytes isolated from the BM, 
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-/- and splenic DCs with C. albicans. We did not observe a significant difference in neutrophil fungicidal activity of Cblb −/− , Cblb C373A/C373A , and Cblb +/+ cells. However, Cblb −/− or Cblb C373A/C373A BM-Ms, BM-DCs, BM monocytes and splenic DC showed an increased fungicidal activity, as compared to that in Cblb +/+ cells (Fig. 3a) . Of note, rates of phagocytosis were comparable between the BM-Ms and BM-DCs of all three genotypes ( Supplementary Fig. 3a ,b).
Compatible with a more prominent role for Cblb in antifungal responses by DCs and macrophages, we observed higher levels of CBLB in BM-DCs and BM-Ms than in neutrophils, in both C. albicans-infected and uninfected cells (Supplementary Fig. 3c ). Thus, CBLB controls the fungicidal activity of BM-Ms, BM-DCs, as well as in BM monocytes and splenic DCs. Pharmacologic inhibition of phagocytosis, using the smallmolecule dynamin inhibitor dynasore, abrogated BM-DC-mediated killing. Similarly, the blocking of dectin-1 significantly reduced C. albicans killing and abrogated the effects of the Cblb deficiency (Fig. 3b) . In addition, pharmacologic inhibition of SYK with the ATP-competitive SYK inhibitor R406 almost completely abrogated C. albicans killing (Fig. 3c) . We next measured whether a lack of CBLB protein or of its ligase function affects the ability of immune cell lineages to produce ROS, which is essential for the killing of C. albicans 36 . Cblb −/− or Cblb C373A/C373A -expressing BM neutrophils did not substantially differ from Cblb +/+ BM neutrophils with respect to ROS production in response to C. albicans (Supplementary Fig. 3d ). However, the increased fungicidal activity of Cblb −/− or Cblb C373A/C373A -expressing BM-Ms, BM-DCs, BM monocytes, and splenic DCs correlated with increased C. albicans-induced ROS production as compared to that by Cblb-sufficient cells ( Supplementary Fig. 3e-h ). Additionally, we observed that loss of CBLB markedly enhanced the production of ROS by BM-DCs that were stimulated with clinical isolates of Candida glabrata, Candida krusei, and C. dubliniensis ( Supplementary Fig. 3i-k) . Thus, loss of CBLB enhances the immune response to several clinically relevant fungal pathogens. . In a-c,f,i, data are shown as mean ± s.d. For a,b, one representative experiment of five independent experiments is shown. In c-j, one representative experiment of three independent experiments is shown. *P < 0.05, **P < 0.01, ***P < 0.001; n.s., not significant; by Student's t-test (a-c,f), two-way ANOVA (d,e,g,i), or log-rank test (j). C. albicans stimulation of BM-DCs activates the caspase-8-dependent inflammasome 21, 37 . We indeed observed substantially increased caspase-8 activity (Supplementary Fig. 4a ) and increased dectin-1-dependent interleukin (IL)-1β secretion in C. albicansstimulated Cblb −/− or Cblb C373A/C373A -expressing BM-DCs , as compared to those in Cblb +/+ BM-DCs (Supplementary Fig. 4b ), which could be blocked by SYK inhibition (Supplementary Fig. 4c ). We found similarly increased release of IL-1β by C. albicans-stimulated Cblb −/− or Cblb C373A/C373A -expressing BM-Ms, as compared to that by Cblb +/+ BM-Ms (Supplementary Fig. 4d) .
To monitor the C. albicans-induced transcriptional response, we assessed mRNA levels of key pro-inflammatory cytokines. We observed substantially increased expression of the genes encoding IL-1β, IL-6, tumor necrosis factor (TNF), IL-23, and IL-12 in Cblb −/− or Cblb C373A/C373A -expressing BM-DCs, as compared to that in Cblb +/+ BM-DCs (Supplementary Fig. 4e ). Increased transcription correlated with increased secretion of the pro-inflammatory cytokines IL-6 and TNF by Cblb −/− and Cblb C373A/C373A -expressing BM-DCs than that by Cblb +/+ cells ( Supplementary Fig. 4f,g ). Blocking dectin-1 reduced the release of IL-6 and TNF for all three genotypes ( Supplementary  Fig. 4f,g ). Again, pharmacologic inhibition of SYK almost completely abrogated the release of IL-6 and TNF by C. albicansstimulated BM-DCs of all three genotypes (Supplementary Fig. 4h,i) . C. albicans stimulation also led to substantially increased release of IL-23 and IL-12 by Cblb −/− and Cblb C373A/C373A -expressing BM-DCs (Supplementary Fig. 4j,k) and of IL-6 and TNF by Cblb −/− and Cblb C373A/C373A -expressing BM-Ms (Supplementary Fig. 4l,m) , as compared to that by Cblb +/+ cells. Furthermore, we observed an increase in IL-1RA secretion when C. albicans-stimulated Cblb −/− BM-DCs were compared to Cblb +/+ cells (Supplementary Fig. 4n) .
To further test for the contribution of dectin-1 to the increased cytokine production by Cblb-deficient BM-DCs, we stimulated BM-DCs with zymosan, a yeast cell wall homogenate, or curdlan, a purified β-glucan. Stimulation with zymosan or the dectin-1 agonist curdlan resulted in increased release of IL-1β, IL-6, and TNF by Cblb −/− and Cblb C373A/C373A -expressing BM-DCs, as compared to that by Cblb +/+ cells ( Supplementary Fig. 5a-f) . Notably, we did not observe significant differences in the secretion of IL-6 and TNF in response to stimulation with the TLR4 agonist LPS or the TLR9 agonist CpG, when Cblb −/− and Cblb +/+ BM-DCs were compared ( Supplementary  Fig. 5g-j) . Thus, Cblb is a key regulator of dectin-1-and SYK-mediated responses of BM-DCs and BM-Ms to C. albicans infections.
To address whether the observed differences in vitro could be recapitulated in immune cells that are recruited to inflammatory sites, we challenged Cblb −/− and Cblb +/+ mice by intraperitoneal infection with C. albicans and assessed their antifungal activity 24 h later. Loss of Cblb led to an enhanced ROS response by cells that infiltrated the peritoneal cavity (Fig. 3d,e) . Likewise, the fungicidal activity of Cblb −/− infiltrates was increased, as compared to that of Cblb +/+ infiltrates (Fig. 3f) . To test for the ability of infiltrating neutrophils or of monocytes and macrophages to produce ROS, we FACS-purified these cell types from total C. albicans-induced infiltrates. We observed increased ROS production by infiltrating Cblb −/− monocytes and macrophages, but not neutrophils, as compared to that by Cblb +/+ cells (Fig. 3g,h) . Additionally, we observed an increase in amounts of IL-6, TNF, and IL-1RA in peritoneal lavages from Cblb −/− mice than in those from Cblb +/+ mice (Supplementary Fig. 5k ).
Our data indicated that the protective effect of Cblb deficiency against fungal infection was mediated by phagocytes but not neutrophils. To test for the role of Cblb in phagocytes, we depleted phagocytes, but not neutrophils, 24 h before and 24 h after systemic infection with C. albicans, using clodronate liposomes 38, 39 . Although the depletion of phagocytes leads to a significant increase in weight loss when clodronate-liposome-and PBS-liposome-treated cohorts were 38 , the difference between the Cblb +/+ and Cblb −/− cohorts was abolished owing to phagocyte depletion (Fig. 3i) . Likewise, the survival benefit of mice in the Cblb −/− , as compared to that in the Cblb +/+ , cohort was abrogated after phagocyte depletion (Fig. 3j) . These data show that Cblb deficiency in phagocytic cells is critical for the observed beneficial effect in fungal infections.
Loss of CBLB enhances CLR-mediated signaling in response to C. albicans
To assess whether loss of CBLB or of CBLB ligase function altered the signaling response mounted by BM-DCs, we analyzed changes in global tyrosine phosphorylation in response to C. albicans infection. We observed a strong increase in tyrosine phosphorylation in response to C. albicans stimulation in Cblb −/− and Cblb C373A/C373A -expressing BM-DCs, as compared to that in control Cblb +/+ BM-DCs (Fig. 4a) . Canonical signaling by CLRs involves activation of the tyrosine kinase SRC and the protein tyrosine phosphatase SHP-2, which subsequently results in the activation of SYK 20 . We observed comparable SRC tyrosine phosphorylation, but increased levels of phosphorylated SHP-2 and SYK in the absence of CBLB or CBLB ligase function, after stimulation of BM-DCs with C. albicans (Fig. 4b) . The more pronounced effect of SYK inhibition, as compared to that for dectin-1 blockade, prompted us to test for a role of CBLB in dectin-1, dectin-2, dectin-3, and Mincle signaling. Although these surface receptors were expressed at comparable levels in Cblb −/− and Cblb +/+ BM-DCs (Supplementary Fig. 6a ), we observed an increase in SYK and SHP-2 phosphorylation in response to heat-killed C. albicans (to activate dectin-1) and C. albicans hyphae (to activate dectin-2 and dectin-3), as well as to trehalose-6,6-dimycolate (to activate Mincle), in the absence of Cblb (Fig. 4c) . Moreover, we observed an increase in phosphorylation of the distal CLR signaling molecules PLC-γ2 and p65 NF-κB in C. albicans-stimulated Cblb −/− and Cblb C373A/C373A -expressing BM-DCs (Fig. 4d) . Cblb −/− BM-DCs also showed increased levels of both phosphorylated SHP-2 ( Fig. 4e ) and phosphorylated SYK (Fig. 4f) following stimulation with C. albicans, as analyzed by confocal microscopy. These data identify a central function for CBLB in regulating CLR signaling in response to C. albicans infection.
CBLB targets SYK, dectin-1, and dectin-2 for ubiquitination
To test whether CBLB could polyubiquitinate CLR signaling molecules, we performed ubiquitination assays. We did not detect polyubiquitination of recombinant SHP-2 (data not shown) but observed robust polyubiquitination of active SYK (Fig. 5a) . The chain linkage type formed by CBLB was analyzed by mass spectrometry, and we identified the unique peptide FAGKQLED, which is derived specifically from Lys48 (K48)-linked ubiquitin chains (Supplementary Fig. 6b ). CBLB substrate specificity is mainly mediated by its amino-terminal tyrosine-kinase-binding (TKB) domain. We show that a truncated CBLB protein (CBLB ), which lacks the carboxy-terminal ubiquitin-associated (UBA) domain but contains the TKB and RING finger domain, still showed polyubiquitination activity toward SYK (Fig. 5a) . As expected, the Cys373Ala mutant of CBLB lacked SYK polyubiquitination activity (Fig. 5a) . Notably, nonphosphorylated inactive SYK showed strongly diminished polyubiquitination by CBLB (Fig. 5b) , consistent with CBLB targeting activated SYK. To test for interactions between SYK and CBLB, we performed co-immunoprecipitation (co-IP) experiments. We observed increased co-IP of SYK with CBLB after stimulation of BM-DCs with C. albicans ( Fig. 5c ). After treatment with the proteasome blocker MG132, we observed an increase in phosphorylated SYK in lysates prepared from Cblb +/+ BM-DCs, but not in those from Cblb −/− BM-DCs, stimulated with C. albicans (Fig. 5d) , indicating that CBLB mediates its effects via proteasomal targeting. These results show that CBLB can ubiquitinate active SYK. Additionally, we addressed whether dectin-1 and dectin-2 might also serve as targets for CBLB-mediated degradation. We thus stimulated BM-Ms with C. albicans or C. albicans hyphae, and tested for dectin-1 and dectin-2 protein levels, respectively. Although dectin-1 and dectin-2 levels decreased over time in control cells, their expression levels remained constant in the absence of Cblb ( Supplementary  Fig. 6c,d) . To test whether dectin-1 and dectin-2 are ubiquitinated in response to fungal stimulation, and if so, whether ubiquitination is dependent on CBLB, we stimulated Cblb −/− and Cblb +/+ cells, immunoprecipitated dectin-1 or dectin-2, and tested for the presence of ubiquitin. We observed ubiquitination of dectin-1 and dectin-2 in response to stimulation with C. albicans or C. albicans hyphae, respectively. This ubiquitination was reduced in the absence of CBLB (Supplementary Fig. 6e,f) . These data show that CBLB tunes CLR signaling by regulating protein levels of dectin-1 and dectin-2, as well as by modulating SYK activity.
Inhibition of CBLB enhances antifungal immunity in vitro and in vivo
On the basis of our data we reasoned that blocking TKB-mediated substrate recognition by CBLB might de-regulate CLR signaling. We thus designed a fusion peptide consisting of the Drosophila Antennapedia homeodomain 39 cell-penetrating peptide and a phosphorylated peptide derived from SYK that encompasses Tyr317 (Y317), which has been reported to be required for ligase-mediated targeting of SYK by CBL family members 33, 40, 41 (Fig. 5e) . Pre-incubation of CBLB with this CBLB-TKB-binding peptide abrogated in vitro ubiquitination of active SYK (Fig. 5f) . Additionally, we monitored SYK-dependent ROS production in the presence of the CBLB-TKB-binding peptide. Notably, peptide interference massively increased ROS production by BM-DCs in response to C. albicans stimulation (Fig. 5g) . The observed effect even surpassed the increase in ROS production in Cblb −/− cells. Because our peptide-interference strategy potentially inhibits TKB-mediated substrate recognition by all CBL family ligases (CBL, CBLB, and CBLC), these data suggest that CBL family ligases may function in a partly redundant manner. Consistent with this hypothesis, we observed an increased sensitivity to CBLB-TKBpeptide-mediated interference in BM-DCs lacking CBLB, as compared to that in CBLB-sufficient cells (Supplementary Fig. 6g) . Notably, the CBLB-TKB-binding peptide also increased the fungicidal activity of BM-DCs after C. albicans infection (Fig. 5h) .
The observed in vitro efficacy of our inhibitory peptide prompted us to investigate its activity in vivo. We thus infected Cblb −/− and Cblb +/+ littermates with C. albicans and treated them twice with the inhibitory CBLB-TKB-binding peptide (100 µg, by intraperitoneal (i.p.) injection; at day 0 and day 2), or left them untreated. Notably, this treatment had a significant protective effect on Cblb +/+ mice, as compared to untreated Cblb +/+ controls, as evidenced by reduced weight loss and delayed mortality (Fig. 6a) . Moreover, peptide treatment led to a decrease in blood urea nitrogen levels, indicating reduced kidney damage (Fig. 6b) . Peptide treatment did not confer any protective effect on Cblb −/− mice (Supplementary Fig. 6h) . Reducing the concentration of the TKB-binding-peptide by fivefold yielded comparable results (Fig. 6c,d and Supplementary Fig. 6i ). 
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In line with the decreased morbidity observed with low-dose peptide treatment, we detected a significantly reduced kidney fungal load in peptide-treated mice (Fig. 6e) . To test for the therapeutic potential of our TKB-binding-peptide in established fungal sepsis, we treated Cblb +/+ mice on day 2 and day 3 (100 µg/injection) after infection. Notably, this treatment regimen completely blocked further weight loss, significantly reduced kidney fungal load 2 d after the second peptide treatment, and protected mice from mortality ( Fig. 6f-h ). Histopathologic analysis showed substantially reduced renal inflammation (Fig. 6i,j) , fungal burden (Supplementary Fig. 6j) , and neutrophil infiltration into the kidneys of peptide-treated mice, as compared to those in untreated controls (Supplementary Fig. 6k) . Thus, the CBLB-TBK-binding peptide enhances antifungal immunity and can protect from lethal C. albicans sepsis.
DISCUSSION
Here we identified a critical role for CBLB in the regulation of innate antifungal immunity. Loss of CBLB or of CBLB ligase activity had a protective effect in systemic or cutaneous C. albicans infections. CBLB was shown to modulate CLR signaling and dampen the fungicidal activity of phagocytes, but not that of neutrophils. Mechanistically, CBLB was found to physically associate with the CLR signalosome, via SYK, after fungal activation. Blocking the activity of the proteasome mimicked the loss of CBLB, with regard to SYK activation, prompting us to identify CBLB target molecules. We observed polyubiquitination of SYK, as well as polyubiquitination of dectin-1 and dectin-2, by CBLB. CBLB thus regulates CLR signaling both by affecting the availability of dectin-1 and dectin-2 and by dampening proximal signaling via SYK. On the basis of the SYK-CBLB interaction, we designed a novel CBLB-TKB-binding peptide to inhibit CBLB function. We could validate the in vitro and in vivo efficacy of this approach by protecting mice from morbidity and mortality induced by systemic fungal infections. Genetic networks required for antifungal immune responses have been unraveled in elegant studies in mice 9, 35 and men 3, [42] [43] [44] [45] [46] [47] . These studies, however, have failed to provide mechanistic insight into the negative regulation of such immune responses. Our study reports CBLB as the first negative regulator of innate antifungal immunity. Current therapeutic strategies exploit the vulnerability of fungi to several classes of antifungal compounds 48 . We propose an alternative approach: directly enhancing immune signaling networks essential for a protective antifungal immune response by targeting CBLB. Our in vitro and in vivo studies show that inhibiting CBLB using a peptide-interference strategy releases the brakes on antifungal immunity and protects mice from otherwise lethal systemic infections with C. albicans.
Although showing beneficial effects in the context of fungal inflammation, inhibiting CBLB might cause undesirable side effects by de-regulating adaptive immunity. It is noteworthy that an association to type I diabetes (T1D) of a SNP within exon 12 of CBLB 49 , and of T1D patients carrying functionally defective variants of CBLB, have been reported 50 . Likewise, Cblb-deficient mice manifest autoimmunity. It will thus be of relevance to assess whether there might be lesssevere adverse effects by transiently inhibiting CBL family members, as compared to the effects resulting from the deletion of Cblb.
Specific inhibition of CBL family ubiquitin ligase activity has, to the best of our knowledge, not been accomplished yet. Although the targeting of the TKB domain has been reported in vitro, the in vivo efficacy of this approach is severely limited by the amounts of peptide required 51 . Based on the molecular mechanism identified in our experiments, we engineered a novel CBLB-TKB-blocking peptide combined with an enhanced peptide delivery system based on the Antennapedia cell-permeable peptide 52 . Treatment of mice with our inhibitory peptide indeed drastically improved immune function toward C. albicans and protected mice from a lethal infection in a therapeutic setting. Thus, our study not only provides novel insights into the negative regulation of antifungal immunity, but it also suggests a novel conceptual framework for the design of a potentially efficacious and specific approach to enhance innate antifungal immunity.
METHODS
Methods and any associated references are available in the online version of the paper.
to the reaction mixture. Assays were resolved by SDS-PAGE, transferred on a nitrocellulose membrane (GE Healthcare), and blotted with an anti-ubiquitin antibody, or an anti-SYK antibody. See Supplementary Table 1 for antibodies used in this study. and Cys373Ala CBLB . Sequences encoding CBLB and Cys373Ala CBLB were cloned into the pGEX-2TK vector to obtain gluthathione-S-transferase (GST) fusion proteins. Expression in E. coli BL21 was induced with 0.3 mM isopropyl-d-thiogalactopyranoside at OD 600 nm of 1.0 in Terrific Broth medium (Sigma-Aldrich), and incubated overnight at 20 °C. Cells were lysed in lysis buffer (20 mM Tris-HCl pH 7.5, 100 mM NaCl, 1mM EDTA, 0.5% Triton X-100), sonicated briefly three times, and incubated overnight with glutathione-sepharose 4B (GE Helathcare) at 4 °C. Subsequently, sepharose beads were washed five times with lysis buffer, and bound proteins were eluted with elution buffer (50 mM Tris-HCl, pH 8.0, and 20 mM reduced glutathione). Proteins in the eluates were tested for size and purity with SDS-PAGE and western blotting.
Production of recombinant CBLB
Histopathology. For histopathology analyses, kidneys were fixed in 10% neutralbuffered formalin, processed according to standard procedures, embedded in paraffin, and sectioned. 2-µm-thick sections were stained with hematoxylin and eosin (H&E), periodic-acid-Schiff (PAS), or anti-Ly-6G (BioLegend; clone 1A8). Immunohistochemistry was performed with a primary antibody dilution of 1:100 with DAB enhancement after antigen retrieval (BOND Epitope Retrieval kit, Leica). 4-µm sections were stained with Gomori methenamine silver (GMS; Merck). Stained slides were scanned using a Pannoramic slide scanner (3D Histech) and evaluated for severity of inflammation and intra-lesional fungal burden. Renal inflammation was scored based upon H&E and PAS stainings (proportion of renal parenchyma and/or pelvis involved by tubulointerstitial nephritis and/or pyelonephritis) as not significant (score 0), less than 10% (score 1), 10-25% (score 2), 25-50% (score 3), or greater than 50% (score 4). The intra-lesional fungal burden was based upon PAS and GMS stainings as not significant (score 0), scant presence in less than 10% of inflammatory foci (score 1), mild-to-moderate presence in 10-25% of inflammatory foci (score 2), moderate-to-significant presence in 25-50% of inflammatory foci (score 3), or significant presence in more than 50% of inflammatory foci (score 4). Definiens Tissue Studio (Definiens, Inc.) software was applied to evaluate the extent of infiltration by Ly-6G + cells in affected kidneys. Regions and cells of interest were manually classified in representative areas of slides to train the software algorithm to identify Ly-6G-positive target objects and exclude non-target objects. Target objects were identified on the basis of morphology and positive immunohistochemical staining. The optimized algorithm was then applied to analyze all slides automatically. The validity of the analysis was confirmed by histopathologic verification of representative slides from both groups.
Peptide synthesis. Solid-phase peptide synthesis (SPPS) was used for TKB binding peptide synthesis on an ABI 433a Peptide Synthesizer (Applied Biosystems). Peptides were purified with an Ultimate 3000 RP-HPLC system (Thermo Scientific), and analyzed with a 4,800 MALDI-TOF/TOF analyzer (ABSciex). Lyophilized peptides were resolved in PBS and stored at −80 °C.
Immunofluorescence. BM-DCs were seeded on µ-slides (IBIDI) 24 h before infection with C. albicans. After infection, cells were fixed in 4% PFA on ice for 20 min, permeabilized (0.2% Triton X-100 in PBS) for 10 min at room temperature, and blocked (3% BSA in PBS) for 1 h at room temperature. Subsequently, cells were incubated with primary antibodies against SYK (1:100) or SHP-2 (1:100) in 3% BSA, overnight. Cells were then washed in PBS and incubated with an anti-rabbit-Alexa555 antibody (1:500) in 3% BSA at room temperature for 1 h. After washing in PBS, cells were counterstained with DAPI and directly imaged with a Zeiss LSM780 confocal microscope. Please see Supplementary  Table 1 for antibodies used in this study.
NanoLC/MS analysis. The nano-HPLC system used for this study was an UltiMate 3000 HPLC RSLC nano system (Thermo Scientific) coupled to a Q Exactive Plus mass spectrometer (Thermo Scientific), equipped with a Proxeon nanospray source (Thermo Scientific). Peptides were loaded on a trap column (Thermo Fisher Scientific, Amsterdam, Netherlands; PepMap C18, 5 mm × 300 µm ID, 5-µm particles, 100-Å pore size) at a flow rate of 25 µl/min using 0.1% trifluoroacetic acid as the mobile phase. After 10 min the trap column was switched in line with the analytical column (Thermo Fisher Scientific, Amsterdam, Netherlands; PepMap C18, 500 mm × 75 µm ID, 2 µm, 100 Å). Peptides were eluted by using a flow rate of 230 nl/min and a binary 2-h gradient for 165 min. The gradient was started with 98% water/formic acid (99.9/0.1; vol/vol) and 2% water/acetonitrile/formic acid (19.92/80/0.08; vol/vol/vol), and increased to 35% water/formic acid (99.9/0.1; vol/vol) and 65% water/acetonitrile/formic acid (19.92/80/0.08; vol/vol/vol) over 120 min, followed by a gradient to 10% water/formic acid (99.9/0.1; vol/vol) and 90% water/acetonitrile/formic acid (19.92/80/0.08; vol/vol/vol) over 5 min, kept at this ratio for 5 min and subsequently decreased over 2 min back to 98% water/formic acid (99.9/0.1; vol/vol) and 2% water/acetonitrile/formic acid (19.92/80/0.08; vol/vol/vol) for equilibration at 30 °C. The Q Exactive mass spectrometer was operated in data-dependent mode, using a full scan (m/z range 370-1,650, nominal resolution of 70,000, and target value of 3 × 10 6 ) followed by MS/MS scans of the 12 most-abundant ions. MS/MS spectra were acquired using normalized collision energy 27%, isolation width of 2, and the target value of 1 × 10 5 . Precursor ions selected for fragmentation (charge state 2 and higher) were put on a dynamic exclusion list for 10 s. The underfill ratio was set to 20%, resulting in an intensity threshold of 4 × 10 4 . The 'peptide match' and the 'exclude isotopes' features were enabled.
Mass spectrometry data analysis. For peptide identification the .RAW files were loaded into Proteome Discoverer (version 1.4.0.288, Thermo Scientific). All created MS/MS spectra were searched by using the search engine node MS Amanda 56 against the Flybase sequence database (22,256 sequences; 20,222,850 residues) and also against the Swissprot sequence database, using the taxonomy human (20,170 sequences; 11,318,213 residues). The following search parameters were used: β-methylthiolation on cysteine was set as a fixed modification; oxidation on methionine; acetylation on lysine; phosphorylation on serine, threonine and tyrosine; deamidation on asparagine and glutamine; and ubiquitinylation on lysine were set as variable modifications. Monoisotopic masses were searched within unrestricted protein masses for tryptic peptides. The peptide mass tolerance was set to ± 5 p.p.m. and the fragment mass tolerance to ± 0.03 Da. The maximal number of missed cleavages was set to 2. The result was filtered to 1% false discovery rate (FDR), using the Percolator algorithm integrated in Proteome Discoverer. The localization of the sites of variable modifications within the peptides was performed with the tool ptmRS, integrated in Proteome Discoverer, and based on phosphoRS 57 .
Data analysis and statistical analysis. All values in the paper are given as means ± s.d., unless stated otherwise. All in vitro experiments were reproduced 3-5 independent times. In vivo experiments were reproduced 2-6 times.
Figures and statistical analyses were generated using GraphPad Prism software (GraphPad Software). No mice were excluded from the analyses, and histopathologic analyses using Definies Tissue Studio software were performed in a blinded manner. Mice were allocated to experimental groups based on their genotypes and were randomized within their sex-and age-matched groups. Because mice were inbred and sex-and age-matched, we assumed similar variances between experimental cohorts. An a priori sample size estimation was not performed. Group sizes were based on the empirically assessed variability of the model systems or assays used, and groups contained as many mice as possible to minimize type I and type II errors. Data were analyzed by using the unpaired two-tailed Student's t-test, or two-way ANOVA, as indicated. For survival analyses, log-rank tests were performed. P < 0.05 was accepted as statistically significant.
